Skip to content
value.today

Actuate Therapeutics, Inc.

ACTU
$22 Mmarket cap on Oct 30, 2026
Compare
World rank
#23,977
Revenue
—
For year ending December-2025
Net income
$-22 M
SEC filing
Employees
12
As of December 31, 2025
SEC filing

Actuate Therapeutics, Inc. in brief

Actuate Therapeutics, Inc. is a listed company in the Biotechnology industry, based in Fort Worth, Texas, USA. Its market value was $22 M on 30 October 2026, which makes it the 23,977th largest listed company in the world and the 4,125th largest in the USA on this site. It employs about 12 people. Its shares trade under the symbol ACTU (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Actuate Therapeutics, Inc.

We are a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3. We are developing elraglusib, an ATP-competitive small molecule that is designed to enter cancer cells and block the function of the enzyme glycogen synthase kinase-3 beta, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion. We believe that the blockade of GSK-3β signaling ultimately results in the death of the cancer cells and the regulation of anti-tumor immunity. There are no approved high-affinity inhibitors of GSK-3β and we believe elraglusib is one of the most advanced GSK-3β inhibitors in clinical development. Elraglusib was originally known as 9-ING-41 but was granted the elraglusib International Nonproprietary Names and United States Adopted Names generic name in 2021.

From the company's annual report filed with the US SEC: read the report

Actuate Therapeutics, Inc. timeline

2 events, 2015–2024
  1. 2015
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. 2024
  4. 🔔
    Initial public offering
    Final prospectus filed with the SEC on 13 August 2024; shares registered for exchange trading on 12 August 2024.

Events of Actuate Therapeutics, Inc. from SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$8 M$15 M$23 M$31 M

World rank over time

▼ down 721 places since 2026
2026-10-14: #23288#23,28820262026-10-30: #24009#24,0092026

Rank in USA: #4,032 (Oct 2026) · #4,128 (Oct 2026)

Key ratios

market cap and latest results
P/E ratio
n/m (loss)
Price / sales
—
Price / book
2.8×
Free cash flow yield
—
Net margin
—
Operating margin
—
Return on equity
-280.7%
Liabilities / assets
43.5%
Profit per employee
$-1.9 M

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2023: revenue —, net income $-25M—FY23Fiscal year ending Dec 2024: revenue —, net income $-27M—FY24Fiscal year ending Dec 2025: revenue —, net income $-22M—FY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025——$-23M$-22M—
Dec 2024——$-25M$-27M—
Dec 2023——$-25M$-25M—

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-19M——$-1.06—
Dec 2024$-22M——$-3.26—
Dec 2023$-22M——$-17.24—

Quarterly results

USD · three months to · source: SEC filings
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue —, net income $-6M—Dec ’24Three months to Mar 2025: revenue —, net income $-6M—Mar ’25Three months to Jun 2025: revenue —, net income $-6M—Jun ’25Three months to Sep 2025: revenue —, net income $-5M—Sep ’25Three months to Dec 2025 (from the annual report): revenue —, net income $-5M—Dec ’25Three months to Mar 2026: revenue —, net income $-6M—Mar ’26Three months to Jun 2026: revenue —, net income $-5M—Jun ’26Three months to Sep 2026: revenue —, net income $-3M—Sep ’26

Latest quarter to Sep 2026: revenue —, net income $-3M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Jun 2026.

SEC filings

Official filings of Actuate Therapeutics, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
—
Operating income
$-23 M
Net income
$-22 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$14 M
Total liabilities
$6 M
Total equity
$8 M

As of December-2025

Top 40 institutional investors in Actuate Therapeutics, Inc.#

As of Sep 30, 2026
40 institutions held 13.3 M shares (about 55.4% of the shares outstanding) on Sep 30, 2026. The ten largest hold 53.9%. Source: SEC Form 13F filings, filed through Nov 16, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in Actuate Therapeutics, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1BIOS Capital Management, LP10,049,9960 (0.00%)41.85%$8 MNov 13, 2026
2Voss Capital, LP1,899,305+174,305 (+10.10%)7.91%$1 MNov 16, 2026
3Vanguard Capital Management LLC393,4330 (0.00%)1.64%$0 MNov 13, 2026
4Geode Capital Management, LLC104,315-8,239 (-7.32%)0.43%$0 MNov 6, 2026
5Texas Capital Bank Wealth Management Services Inc102,6120 (0.00%)0.43%$0 MNov 9, 2026
6Palogic Value Management, L.P.100,000-100,000 (-50.00%)0.42%$0 MNov 16, 2026
7Millennium Management LLC90,195-6,489 (-6.71%)0.38%$0 MNov 16, 2026
8ABS Investment Management LLC73,1860 (0.00%)0.30%$0 MNov 16, 2026
9BlackRock, Inc.66,944-23,091 (-25.65%)0.28%$0 MNov 13, 2026
10Vanguard Fiduciary Trust Co54,4970 (0.00%)0.23%$0 MNov 13, 2026
11Rock Creek Group LLC50,000+10,737 (+27.35%)0.21%$0 MNov 9, 2026
12Sfmg, LLC50,000+17,000 (+51.52%)0.21%$0 MNov 13, 2026
13HighTower Advisors, LLC36,430-31 (-0.09%)0.15%$0 MNov 10, 2026
14Susquehanna International Group, LLP25,076-3,106 (-11.02%)0.10%$0 MNov 16, 2026
15Bridgeway Capital Management, LLC23,106-376 (-1.60%)0.10%$0 MNov 16, 2026
16Empowered Funds, LLC23,106New0.10%$0 MNov 13, 2026
17State Street Corp21,8500 (0.00%)0.09%$0 MNov 12, 2026
18Northern Trust Corp21,2200 (0.00%)0.09%$0 MNov 16, 2026
19Gleason Group, Inc.19,0280 (0.00%)0.08%$0 MOct 15, 2026
20Northwestern Mutual Wealth Management Co18,5180 (0.00%)0.08%$0 MNov 13, 2026
21LPL Financial LLC11,915-50 (-0.42%)0.05%$0 MNov 6, 2026
22Sowell Financial Services LLC10,9730 (0.00%)0.05%$0 MOct 23, 2026
23Green Ridge Wealth Planning LLC10,0000 (0.00%)0.04%$0 MOct 8, 2026
24FNY Investment Advisers, LLC8,280New0.03%$0 MOct 16, 2026
25Global Retirement Partners, LLC6,2500 (0.00%)0.03%$0 MNov 10, 2026
Show all 40: investors 26 to 40
Institutional investors 26 to 40 in Actuate Therapeutics, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
26Nuveen, LLC6,146New0.03%$0 MNov 10, 2026
27Russell Investments Group, Ltd.5,932+5,259 (+781.43%)0.02%$0 MNov 6, 2026
28Vanguard Global Advisers, LLC5,1020 (0.00%)0.02%$0 MNov 13, 2026
29UBS Group AG2,707-827 (-23.40%)0.01%$0 MNov 10, 2026
30Wells Fargo & Company/mn2,440-6 (-0.25%)0.01%$0 MNov 16, 2026
31Morgan Stanley2,147-1,343 (-38.48%)0.01%$0 MNov 13, 2026
32Royal Bank Of Canada1,332+849 (+175.78%)0.01%$0 MNov 16, 2026
33Osaic Holdings, Inc.1,0000 (0.00%)0.00%$0 MNov 12, 2026
34BNP Paribas Financial Markets690-300 (-30.30%)0.00%$0 MNov 12, 2026
35FMR LLC28-3,259 (-99.15%)0.00%$0 MNov 10, 2026
36IFP Advisors, Inc26-47 (-64.38%)0.00%$0 MOct 16, 2026
37Tower Research Capital LLC (TRC)17-3,617 (-99.53%)0.00%$0 MNov 16, 2026
38EverSource Wealth Advisors, LLC2-263 (-99.25%)0.00%$0 MNov 4, 2026
39Barclays PLC1-420 (-99.76%)0.00%$0 MNov 6, 2026
40Caitong International Asset Management Co., Ltd1New0.00%$0 MOct 29, 2026

Mutual funds holding Actuate Therapeutics, Inc.#

28 funds hold shares worth $1 M (about 2.7% of the company). Since their previous reports 18 added shares and 27 sold, buying $0 M net.
Mutual funds holding Actuate Therapeutics, Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc.287,385$0 M1.2%<0.01%+1250%Jun 30, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.106,048$0 M0.44%<0.01%+1245%Jun 30, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC51,919$0 M0.22%<0.01%+10.0%May 31, 2026
🇺🇸 Vanguard Russell 2000 Index FundThe Vanguard Group, Inc.48,395$0 M0.20%<0.01%+4.0%May 31, 2026
🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors38,230$0 M0.16%<0.01%+2204%Jun 30, 2026
🇺🇸 Ultra-Small Company Market FundBridgeway Capital Management, LLC23,482$0 M0.10%0.02%+923%Jun 30, 2026
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC15,885$0 M0.07%<0.01%no changeMay 31, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC13,591$0 M0.06%<0.01%no changeMay 31, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC12,252$0 M0.05%<0.01%+12%May 31, 2026
🇺🇸 iShares Russell 2000 ETFBlackRock Fund Advisors13,249$0 M0.06%<0.01%−4.0%Jun 30, 2026
🇺🇸 Vanguard Russell 2000 Growth Index FundThe Vanguard Group, Inc.8,845$0 M0.04%<0.01%+3.1%May 31, 2026
🇺🇸 Small Cap Index FundThe Variable Annuity Life Insurance Company5,490$0 M0.02%<0.01%no changeMay 31, 2026
🇺🇸 iShares Russell 2000 Growth ETFBlackRock Fund Advisors5,506$0 M0.02%<0.01%−0.1%Jun 30, 2026
🇺🇸 Bridge Builder Small/Mid Cap Growth FundOLIVE STREET INVESTMENT ADVISERS LLC1,738$0 M<0.01%<0.01%+1250%Jun 30, 2026
🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC1,700$0 M<0.01%<0.01%+1250%Jun 30, 2026
🇺🇸 Master Small Cap Index SeriesBlackRock Advisors, LLC755$0 M<0.01%<0.01%−0.0%Jun 30, 2026
🇺🇸 ProShares Russell 2000 High Income ETFPROSHARE ADVISORS LLC448$0 M<0.01%<0.01%+8.7%May 31, 2026
🇺🇸 ProShares Ultra Russell2000PROSHARE ADVISORS LLC350$0 M<0.01%<0.01%−40%May 31, 2026
🇺🇸 ProShares UltraPro Russell2000PROSHARE ADVISORS LLC351$0 M<0.01%<0.01%−40%May 31, 2026
🇺🇸 EQ/2000 Managed Volatility PortfolioEquitable Investment Management Group, LLC421$0 M<0.01%<0.01%−0.5%Jun 30, 2026
🇺🇸 Small-Cap Index PortfolioPacific Life Fund Advisors LLC239$0 M<0.01%<0.01%−1.8%Jun 30, 2026
🇺🇸 BlackRock Small Cap Index V.I. FundBlackRock Advisors, LLC108$0 M<0.01%<0.01%+2.7%Jun 30, 2026
🇺🇸 NVIT Small Cap Index FundNATIONWIDE FUND ADVISORS108$0 M<0.01%<0.01%+3.4%Jun 30, 2026
🇺🇸 PD Small-Cap Growth Index PortfolioPacific Life Fund Advisors LLC46$0 M<0.01%<0.01%+4.4%Jun 30, 2026
🇺🇸 Goldman Sachs Absolute Return Tracker FundGoldman Sachs Asset Management, L.P.54$0 M<0.01%<0.01%+1485%Jun 30, 2026
🇺🇸 EQ/Franklin Small Cap Value Managed Volatility PortfolioEquitable Investment Management Group, LLC55$0 M<0.01%<0.01%+4.4%Jun 30, 2026
🇺🇸 EQ/Morgan Stanley Small Cap Growth PortfolioEquitable Investment Management Group, LLC75$0 M<0.01%<0.01%+3.7%Jun 30, 2026
🇺🇸 ATM Small Cap Managed Volatility PortfolioEquitable Investment Management Group, LLC92$0 M<0.01%<0.01%+3.2%Jun 30, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 28 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at Actuate Therapeutics, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$50 K
1 purchase, 1 insider
Sold, 12 months
$1.6 M
1 sale, 1 insider
Net, 12 months
-$1.6 M
open market only
Insiders on file
11
since
$4.0 M-$1.6 M$0Aug 2024: bought $4.0 M (6 trades), sold $375 K (10 trades)Aug 24Jun 2025: bought $500 K (3 trades), sold $0 (0 trades)JunJan 2026: bought $0 (0 trades), sold $1.6 M (1 trades)Jan 26Oct 2026: bought $50 K (1 trades), sold $0 (0 trades)Oct
Bought (open market)Sold (open market)Hover a month for the totals
Actuate Therapeutics, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Daniel M. SchmittPresident, CEO and Director, DirectorBuy+140,844$0.355$50 K442,560Form 4
filed Daniel M. SchmittPresident, CEO and Director, DirectorOption exercise+272,056——422,237Form 4
filed Daniel M. SchmittPresident, CEO and Director, DirectorShares withheld for tax-120,521$1.010$122 K301,716Form 4
filed Daniel M. SchmittPresident, CEO and Director, DirectorOption exercise+272,055——272,055Form 4
filed Daniel M. SchmittPresident, CEO and Director, DirectorShares withheld for tax-121,874$4.330$528 K150,181Form 4
filed Todd S. ThomsonDirector, 10% ownerSellindirect-280,000$5.800$1.6 M904,795Form 4
filed BIOS Actuate Co-Invest I, LPDirector, 10% ownerBuyindirect+71,428$7.000$500 K196,428Form 4
filed BIOS Fund II, LPDirector, 10% ownerBuyindirect+71,428$7.000—196,428Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Actuate Therapeutics, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
1.3 M
5.6% of shares · 2.12 days to cover
Reg SHO threshold list
7 days
in the last 90 days
Shares sold short, last 24 reportsAll stocks →

Fails to deliver

  • : 61,372 shares at $0.37
  • : 14,998 shares at $0.38
  • : 23,484 shares at $0.40
  • : 3,139 shares at $0.48
  • : 28,495 shares at $0.52

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Actuate Therapeutics, Inc. scorecard#

Passes 2 of the 9 checks that could be worked out. Fiscal year 2025; market cap of Oct 30, 2026.

  • Valuation1 of 3
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✓Price to book below its peers' median2.8×Price to book 2.8× against Biotechnology's median of 2.9×.
    • –Price to sales below its peers' medianNo Price to sales on file.
    • –Free cash flow yield above 5%No free cash flow yield on file.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth0 of 1
    • –Revenue grew in the newest yearRevenue of the year before is not on file.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • ✗Earnings per share grew in the newest year-1.06 vs -3.26Diluted EPS -1.06 in fiscal 2025 against -3.26 the year before (report's currency).
    • –Net income higher than five years earlierNet income of five years earlier is not on file.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability0 of 2
    • ✗Profitable in the newest year-$22 MNet income -$22 M in fiscal 2025.
    • –Profitable in each of the last five yearsFive years of net income are not on file.
    • –Operating margin above its peers' medianNo operating margin on file.
    • ✗Return on equity above 15%-554.4%-554.4% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health1 of 2
    • ✓Short-term assets cover short-term liabilities2.4×Current ratio 2.39 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returns0 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year151.1%Diluted shares up 151.1% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Actuate Therapeutics, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Actuate Therapeutics, Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023
Income statement
Research and development101922
General and administrative126.53.3
Operating expenses222525
Operating income−22−25−25
Interest and finance income0.30.20.4
Interest expense and finance costs0.00.00.0
Other non-operating income (expense)0.3−2.10.2
Income tax0.00.00
Net income attributable to shareholders−22−27−25
Earnings per share, basic-1.06-3.26-17.24
Earnings per share, diluted-1.06-3.26-17.24
Shares, weighted average (basic)218.41.4
Shares, weighted average (diluted)218.41.4
Balance sheet
Cash and cash equivalents138.63.0
Other current assets0.50.60.0
Current assets149.23.0
Total assets149.33.0
Accounts payable1.51.93.4
Current liabilities5.78.86.9
Non-current liabilities0.40.41.5
Total liabilities6.19.28.4
Retained earnings−155−132−105
Shareholders' equity7.90.1−100
Total liabilities and equity149.33.0
Shares outstanding23201.7
Cash-flow statement
Share-based compensation6.02.00.4
Cash from operating activities−19−22−22
Shares issued3.80—
Cash from financing activities24284.1
Report10-K10-K10-K

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

Where Actuate Therapeutics, Inc. operates: 2 countries#

Countries where the company has its headquarters, an office, subsidiaries, a branch or reported revenue. 1 subsidiaries on file.

Actuate Therapeutics, Inc.: countries of operation
CountryPresenceRevenue there
🇺🇸 USAHeadquarters1 office—
🇮🇪 Ireland1 subsidiary—

Source: GLEIF legal-entity register, SEC Exhibit 21 and annual reports, office addresses on file. A country without subsidiaries or offices on record is not listed even if the company sells there. How presence is decided

Events at Actuate Therapeutics, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

Warning signs in the last three years

  • Delisting noticeFiling
  • Delisting noticeFiling
  • Auditor changedFiling

Delisting notice 2 · Auditor changed 1 · Directors and officers 2 · Material agreement 5 · Unregistered share sale 2 · Bylaws or fiscal year changed 1 · Shareholder vote 2

Actuate Therapeutics, Inc.: events reported to the SEC
FiledWhat happenedFiling
Delisting notice8-K
Material agreement8-K
Delisting notice8-K
Shareholder vote8-K
Directors and officers8-K
Material agreement8-K
Material agreement8-K
Material agreementUnregistered share sale8-K
Shareholder vote8-K
Material agreementUnregistered share sale8-K
Auditor changed8-K
Directors and officersBylaws or fiscal year changed8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Oct 30, 2026

Acquisitions and funding#

7 private funding rounds before listing

Private share sales · funding history

Private share sales of Actuate Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jun 2025$5 MPrivate placement after listing$2 to $10 million8equity, optionsSEC
Feb 2024$3 MNo. 7$2 to $10 million1debt, optionsSEC
Sep 2022$19 MNo. 6$10 to $50 million95equitySEC
Nov 2020$14 MNo. 5$10 to $50 million14equitySEC
Oct 2019$7 MNo. 4$2 to $10 million17equity, optionsSEC
Apr 2019$22 MNo. 3$10 to $50 million21equity, optionsSEC
Aug 2018$4 MNo. 2$2 to $10 million18debt, optionsSEC
Mar 2017$3 MNo. 1$2 to $10 million2equitySEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

How Actuate Therapeutics, Inc. compares in Biotechnology

  • Market cap$22 M · higher than 18% of 726
  • Price / book2.8× · lower than 50% of 534

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Actuate Therapeutics, Inc.🇺🇸$22 M———
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 30, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Employees:
As of December 31, 2025
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research, SEC annual report; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Actuate Therapeutics, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Actuate Therapeutics, Inc.'s ranking on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Actuate Therapeutics, Inc.? Suggest a correction